← Back to Clinical Trials
Recruiting NCT05880225

NCT05880225 Reciprocal Imitation Training and Musical Rhythm Sensitivity in Autistic Toddlers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05880225
Status Recruiting
Phase
Sponsor Vanderbilt University Medical Center
Condition Autism
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2023-07-03
Primary Completion 2027-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Months
Max Age 36 Months
Study Type INTERVENTIONAL
Interventions
Reciprocal Imitation Trainingmusic-enhanced Reciprocal Imitation Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2023-07-03 with a primary completion date of 2027-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary goal of this study is to examine rhythm sensitivity as a predictor of response to naturalistic developmental behavioral intervention (NDBIs) in autistic toddlers. Toddlers receive either Reciprocal Imitation Training (RIT), an evidence-based NDBI that supports children's imitation and social communication skills, or a music-enhanced version of RIT. Throughout their participation in the intervention, toddlers will complete study procedures of viewing naturalistic videos of infant-directed singing and other social scenes while eye gaze data is collected.

Eligibility Criteria

Inclusion Criteria: * diagnosis of autism / autism spectrum disorder * 18-36 months of age Exclusion Criteria: * Major hearing or visual impairment (e.g., congenital nystagmus), seizure disorder, genetic syndromes, or gestational age \<=34 weeks.

Contact & Investigator

Central Contact

Miriam Lense

✉ miriam.lense@vumc.org

📞 615-322-3086

Principal Investigator

Miriam Lense

PRINCIPAL INVESTIGATOR

Vanderbilt University Medical Center

Frequently Asked Questions

Who can join the NCT05880225 clinical trial?

This trial is open to participants of all sexes, aged 18 Months or older, up to 36 Months, studying Autism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05880225 currently recruiting?

Yes, NCT05880225 is actively recruiting participants. Contact the research team at miriam.lense@vumc.org for enrollment information.

Where is the NCT05880225 trial being conducted?

This trial is being conducted at Nashville, United States.

Who is sponsoring the NCT05880225 clinical trial?

NCT05880225 is sponsored by Vanderbilt University Medical Center. The principal investigator is Miriam Lense at Vanderbilt University Medical Center. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology